Hip Pain ChronicPENGandIAINCT07427238
Pericapsular Nerve Group Block Added to Intra-articular Corticosteroid Injection in the Treatment of Hip Pain
An observational study of Hip Pain Chronic and Osteoarthritis, Hip, run by Saglik Bilimleri Universitesi at 1 site in Turkey (Türkiye).
Trial summary
Osteoarthritis (OA) is a leading cause of chronic musculoskeletal pain and functional disability worldwide, affecting an increasing number of people. Despite various conservative and interventional treatment approaches, pain, the most important clinical problem in the disease, is suboptimally controlled. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hip Pain Chronic, Osteoarthritis, Hip
- What is being tested?
- Intra-articular injection and Intra-articular injection + PENG blok
- Type of treatment
- Pill or oral medicine, Injection or infusion, Surgery or procedure
- How many people
- 50 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Feb 2025to 2 Sep 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with hip pain lasting longer than 6 months due to hip osteoarthritis that has not improved with conservative methods and who have therefore undergone ultrasound-guided intra-articular steroid + local anesthetic injection and/or PENG block.
Who may be able to join
- Patients with hip pain due to hip osteoarthritis who have undergone hip intra-articular steroid + local anesthetic injection and/or PENG block under ultrasound guidance for this reason
- Persistence of pain for more than 6 months
- Failure of pain treatment with conservative methods
Who cannot join
- Those with inflammatory rheumatic joint disease (rheumatoid arthritis, gout, pseudogout, metabolic joint diseases),
- History of major trauma, hip surgery
- Cognitive dysfunction, history of psychiatric illness
- Hepatic or renal insufficiency
- Local or systemic infection
- Coagulopathy
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Effect of Pericapsular Nerve Group Block Added to Intra-articular Corticosteroid Injection in the Treatment of Hip Pain Due to Osteoarthritis: An Observational Prospective Study
Osteoarthritis (OA) is a leading cause of chronic musculoskeletal pain and functional disability worldwide, affecting an increasing number of people. Despite various conservative and interventional treatment approaches, pain, the most important clinical problem in the disease, is suboptimally controlled. Hip osteoarthritis is a chronic condition characterized by progressive degeneration of the joint cartilage and inflammation of the synovial membrane. The incidence of symptomatic hip OA is estimated to be approximately 25%, and its prevalence is increasing due to the aging of the global population and the rise in obesity (1). Conservative methods such as oral medications and physical therapy modalities are available for its management. However, in some patients, pain persists despite these conservative treatment methods, and ongoing pain significantly impairs patients' daily living activities. There are some interventional treatment methods used in these patients, and the most commonly used methods are intra-articular corticosteroid (CS) and local anesthetic (LA) injections and, in some patients, a pericapsular nerve (PENG) block administered in addition to these injections.
Read the detailed description
In this observational study, we will obtain information on the treatment response of patients who previously underwent hip joint injections guided by ultrasound and PENG block in addition to joint injections for hip pain unresponsive to medical treatment, as well as information that we believe may affect treatment response, such as patient age, gender, and disease duration, by reviewing patient files. The patients' treatment response will be evaluated according to the Visual Analog Scale (VAS) and Western Ontario and McMaster Universities Arthritis (WOMAC) index scores, and the pain scores obtained from the patient records before the procedure and one month, three months, and six months after the procedure will be compared. When examining patients for treatment success, the treatment outcomes of patients who received only intra-articular injections will be compared with those who received intra-articular injections + PENG blocks. Current evidence shows that intra-articular steroid injections provide symptomatic relief in hip OA and are recommended for non-surgical treatment. During the procedure, the patient is placed supine, and following sterile cleaning and draping, the ultrasound probe is placed transversely over the inguinal region. After visualizing the femoral head and femoral artery, vein, and nerve, local anesthesia with 1% lidocaine is applied to the needle insertion site after visualizing the femoral head and neck junction and the articular cartilage. Then, a 22-gauge, 100-mm needle is advanced toward the joint capsule, targeting the junction of the femoral neck and femoral head.After reaching the target area, 2 ml of dexamethasone and 2 ml of 0.025% bupivacaine are injected into the joint.
The pericapular nerve group (PENG) block is a treatment applied to block sensory nerve branches, including the articular branches of the femoral nerve, obturator nerve, and accessory obturator nerve that innervate the anterior joint capsule, and is frequently used in our clinic in conjunction with joint injection for hip pain. During the procedure, the patient is placed supine, and following sterile cleaning and draping, the anterior inferior iliac spine (AIIS) and iliopubic eminence (IPE) are visualized using a convex ultrasound probe. The target for the PENG block is the musculo-fascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. After applying local anesthesia to the skin with 1% lidocaine, a 22-gauge, 100 mm needle is inserted and 2 ml of dexamethasone and 2 ml of 0.025% bupivacaine are injected into the target area. Patients are monitored for possible complications.
The primary objective of our study is to compare the treatment responses of patients diagnosed with hip OA who have undergone hip intra-articular injection and/or PENG block therapy and to investigate the effect of PENG block added to intra-articular injection on pain and functionality. The secondary objective is to evaluate other parameters (age, gender, disease duration, analgesic use, etc.) that may influence treatment outcomes at 6 months. The study protocol was approved by the local ethics committee, and the study was conducted in accordance with the principles of the Declaration of Helsinki.
- Conditions
- Hip Pain Chronic, Osteoarthritis, Hip
- Being tested
- Intra-articular injection, Intra-articular injection + PENG blok
- Keywords
- osteoarthritis, hip pain, intraarthicular injection, pericapsular nerve group block
- Medical subject headings
- Osteoarthritis, Hip, Osteoarthritis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intra-articular injectionProcedure or surgery
Under US guidance, following visualization of the femoral head and neck junction and the articular cartilage, a 22-gauge, 100-mm needle is advanced toward the joint capsule, targeting the junction of the femoral neck and femoral head. Once the target area is reached, 2 ml of dexamethasone and 2 ml of 0.025% bupivacaine are injected into the joint.
Intra-articular injection + PENG blokProcedure or surgery
In addition to intra-articular injection, the anterior inferior iliac spine and iliopubic eminence are visualized under ultrasound guidance. A 22-gauge, 100 mm needle is inserted into the musculo-fascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly, and 2 ml of dexamethasone and 2 ml of 0.025% bupivacaine are injected into the target area.
| Study group | Role | What they receive |
|---|---|---|
| Intra-articular injection | During hip intra-articular injection, the patient is placed supine, and following sterile cleaning and draping, the ultrasound probe is placed transversely in the inguinal region. After visualizing the femoral head and femoral artery, vein, and nerve, local anesthesia with 1% lidocaine is applied to the needle entry site after visualizing the femoral head and neck junction and the joint cartilage. Then, a 22-gauge, 100-mm needle is advanced toward the joint capsule, targeting the junction of the femoral neck and femoral head. Once the target area is reached, 2 ml of dexamethasone and 2 ml of 0.025% bupivacaine are injected into the joint. Receives: Procedure: Intra-articular injection | |
| Intra-articular injection + PENG block | After intra-articularf injection; additionally, during the PENG block, the patient is placed supine, and following sterile cleaning and draping, the anterior inferior iliac spine (AIIS) and iliopubic eminence (IPE) are visualized using a convex ultrasound probe. The target for the PENG block is the musculo-fascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. After applying local anesthesia to the skin with 1% lidocaine, a 22-gauge, 100 mm needle is inserted and 2 ml of dexamethasone and 2 ml of 0.025% bupivacaine are injected into the target area. Patients are monitored for possible complications. Receives: Procedure: Intra-articular injection + PENG blok |
What is being measured
The primary outcome is the main question the study is designed to answer.
Numerical rating scale (NRS)
NRS is a scale that can be used measuring pain. Scores range from 0 (no pain) to 10 (the worst pain)
Measured: Change from baseline to 1st, 3rd and 12th weeks after treatment
Secondary outcomes (1)
The Western Ontario McMaster University Osteoarthritis (WOMAC) Index
The Western Ontario McMaster University Osteoarthritis (WOMAC) Index consists of a total of 24 questions under 3 main headings: 5 questions related to joint pain, 2 questions on joint stiffness, and 17 questions on physical function in daily life. (0 = best score, 96 = worst score). High WOMAC scores indicate increased pain and stiffness, as well as impaired physical function.
Measured: Change from baseline to 1st, 3rd and 12th weeks after treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Feb 2026
- Study start1 Feb 2025
- Primary completion1 Sep 2025
- Study completion2 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hip Pain ChronicStudies of the same condition, open and under way.
- More trials run by Saglik Bilimleri UniversitesiThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- Saglik Bilimleri Universitesi
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Alp Eren Çelenlioğlu, MD, Study director, Gulhane School of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07427238
- Sponsor's protocol ID
- Hip OA pain
- Acronym
- PENGandIAI
- Status last verified
- Feb 2026
- First submitted
- 16 Feb 2026
- Last updated
- 23 Feb 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Pericapsular Nerve Group Block Added to Intra-articular Corticosteroid Injection in the Treatment of Hip Pain Due to Osteoarthritis: An Observational Prospective Study
- ClinicalTrials.gov ID
- NCT07427238
- Acronym / sponsor ID
- PENGandIAI / Hip OA pain
- Conditions
- Hip Pain Chronic, Osteoarthritis, Hip
- Keywords
- osteoarthritis, hip pain, intraarthicular injection, pericapsular nerve group block
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 50 participants (actual)
- Lead sponsor
- Saglik Bilimleri UniversitesiUniversity, hospital or other
- Study start
- 1 Feb 2025 (actual)
- Primary completion
- 1 Sep 2025 (actual)
- Study completion
- 2 Sep 2025 (actual)
- First posted
- 23 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Osteoarthritis (OA) is a leading cause of chronic musculoskeletal pain and functional disability worldwide, affecting an increasing number of people. Despite various conservative and interventional treatment approaches, pain, the most important clinical problem in the disease, is suboptimally controlled. Hip osteoarthritis is a chronic condition characterized by progressive degeneration of the joint cartilage and inflammation of the synovial membrane. The incidence of symptomatic hip OA is estimated to be approximately 25%, and its prevalence is increasing due to the aging of the global population and the rise in obesity (1). Conservative methods such as oral medications and physical therapy modalities are available for its management. However, in some patients, pain persists despite these conservative treatment methods, and ongoing pain significantly impairs patients' daily living activities. There are some interventional treatment methods used in these patients, and the most commonly used methods are intra-articular corticosteroid (CS) and local anesthetic (LA) injections and, in some patients, a pericapsular nerve (PENG) block administered in addition to these injections.
Detailed description
In this observational study, we will obtain information on the treatment response of patients who previously underwent hip joint injections guided by ultrasound and PENG block in addition to joint injections for hip pain unresponsive to medical treatment, as well as information that we believe may affect treatment response, such as patient age, gender, and disease duration, by reviewing patient files. The patients' treatment response will be evaluated according to the Visual Analog Scale (VAS) and Western Ontario and McMaster Universities Arthritis (WOMAC) index scores, and the pain scores obtained from the patient records before the procedure and one month, three months, and six months after the procedure will be compared. When examining patients for treatment success, the treatment outcomes of patients who received only intra-articular injections will be compared with those who received intra-articular injections + PENG blocks. Current evidence shows that intra-articular steroid injections provide symptomatic relief in hip OA and are recommended for non-surgical treatment. During the procedure, the patient is placed supine, and following sterile cleaning and draping, the ultrasound probe is placed transversely over the inguinal region. After visualizing the femoral head and femoral artery, vein, and nerve, local anesthesia with 1% lidocaine is applied to the needle insertion site after visualizing the femoral head and neck junction and the articular cartilage. Then, a 22-gauge, 100-mm needle is advanced toward the joint capsule, targeting the junction of the femoral neck and femoral head.After reaching the target area, 2 ml of dexamethasone and 2 ml of 0.025% bupivacaine are injected into the joint.
The pericapular nerve group (PENG) block is a treatment applied to block sensory nerve branches, including the articular branches of the femoral nerve, obturator nerve, and accessory obturator nerve that innervate the anterior joint capsule, and is frequently used in our clinic in conjunction with joint injection for hip pain. During the procedure, the patient is placed supine, and following sterile cleaning and draping, the anterior inferior iliac spine (AIIS) and iliopubic eminence (IPE) are visualized using a convex ultrasound probe. The target for the PENG block is the musculo-fascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. After applying local anesthesia to the skin with 1% lidocaine, a 22-gauge, 100 mm needle is inserted and 2 ml of dexamethasone and 2 ml of 0.025% bupivacaine are injected into the target area. Patients are monitored for possible complications.
The primary objective of our study is to compare the treatment responses of patients diagnosed with hip OA who have undergone hip intra-articular injection and/or PENG block therapy and to investigate the effect of PENG block added to intra-articular injection on pain and functionality. The secondary objective is to evaluate other parameters (age, gender, disease duration, analgesic use, etc.) that may influence treatment outcomes at 6 months. The study protocol was approved by the local ethics committee, and the study was conducted in accordance with the principles of the Declaration of Helsinki.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intra-articular injection | – | Procedure: Intra-articular injectionDuring hip intra-articular injection, the patient is placed supine, and following sterile cleaning and draping, the ultrasound probe is placed transversely in the inguinal region. After visualizing the femoral head and femoral artery, vein, and nerve, local anesthesia with 1% lidocaine is applied to the needle entry site after visualizing the femoral head and neck junction and the joint cartilage. Then, a 22-gauge, 100-mm needle is advanced toward the joint capsule, targeting the junction of the femoral neck and femoral head. Once the target area is reached, 2 ml of dexamethasone and 2 ml of 0.025% bupivacaine are injected into the joint. |
| Intra-articular injection + PENG block | – | Procedure: Intra-articular injection + PENG blokAfter intra-articularf injection; additionally, during the PENG block, the patient is placed supine, and following sterile cleaning and draping, the anterior inferior iliac spine (AIIS) and iliopubic eminence (IPE) are visualized using a convex ultrasound probe. The target for the PENG block is the musculo-fascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. After applying local anesthesia to the skin with 1% lidocaine, a 22-gauge, 100 mm needle is inserted and 2 ml of dexamethasone and 2 ml of 0.025% bupivacaine are injected into the target area. Patients are monitored for possible complications. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with hip pain lasting longer than 6 months due to hip osteoarthritis that has not improved with conservative methods and who have therefore undergone ultrasound-guided intra-articular steroid + local anesthetic injection and/or PENG block.
Key inclusion criteria (3 listed)
- Patients with hip pain due to hip osteoarthritis who have undergone hip intra-articular steroid + local anesthetic injection and/or PENG block under ultrasound guidance for this reason
- Persistence of pain for more than 6 months
- Failure of pain treatment with conservative methods
Key exclusion criteria (6 listed)
- Those with inflammatory rheumatic joint disease (rheumatoid arthritis, gout, pseudogout, metabolic joint diseases),
- History of major trauma, hip surgery
- Cognitive dysfunction, history of psychiatric illness
- Hepatic or renal insufficiency
- Local or systemic infection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Intra-articular injectionUnder US guidance, following visualization of the femoral head and neck junction and the articular cartilage, a 22-gauge, 100-mm needle is advanced toward the joint capsule, targeting the junction of the femoral neck and femoral head. Once the target area is reached, 2 ml of dexamethasone and 2 ml of 0.025% bupivacaine are injected into the joint. | Procedure or surgery | Intra-articular injection |
| Intra-articular injection + PENG blokIn addition to intra-articular injection, the anterior inferior iliac spine and iliopubic eminence are visualized under ultrasound guidance. A 22-gauge, 100 mm needle is inserted into the musculo-fascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly, and 2 ml of dexamethasone and 2 ml of 0.025% bupivacaine are injected into the target area. | Procedure or surgery | Intra-articular injection + PENG block |
Primary outcome
Numerical rating scale (NRS)
Time frame: Change from baseline to 1st, 3rd and 12th weeks after treatment
NRS is a scale that can be used measuring pain. Scores range from 0 (no pain) to 10 (the worst pain)
1 secondary outcome
The Western Ontario McMaster University Osteoarthritis (WOMAC) Index
Time frame: Change from baseline to 1st, 3rd and 12th weeks after treatment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Feb 2026.
Related trials for Hip Pain Chronic
RecruitingPhase 4
PENG vs L-ESPB With S-ESPB for Analgesia in Total Hip Arthroplasty
Hip Osteoarthritis, Hip Arthropathy
Not yet recruiting
Hip Muscle Strengthening and Calf Myofascial Release in Females With Chronic Plantar Fasciitis
Chronic Planter Fascitis
Recruiting
Studying Melatonin and Recovery in Teens
Juvenile; Scoliosis, Scoliosis Idiopathic
Active, not recruiting
Developing an Opioid Taper Intervention Before Total Joint Arthroplasty
Arthritis Knee, Arthritis Hip
RecruitingObservational study
MDR - PMCF Study for Taperloc Complete Stems
Hip Arthritis, Hip Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alp Eren Çelenlioğlu, MD study director
Gulhane School of Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hip Pain Chronic and Osteoarthritis, Hip, run by Saglik Bilimleri Universitesi at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Numerical rating scale (NRS) (time frame: Change from baseline to 1st, 3rd and 12th weeks after treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Feb 2026.